Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox.
Vizgen is unlocking the power of spatially resolved, single-cell gene expression profiling in intact tissue slices to bring new insight into biological systems and diseases.
Vizgen was founded in 2019 by Xiaowei Zhuang, David Walt, Jeffrey Moffitt, Jiang He and George Emanuel. The company is based in Cambridge, Massachsuetts.
Vizgen's has developed, MERFISH, a quantitative and genome-scale multiplexed imaging technology for identifying nucleic acids in their native cellular and tissue environment. MERFISH leverages error-correcting barcoding schemes and combinatorial labeling and imaging for near 100% detection efficiency and low false-positive rates at high throughput and low cost.
Vizgen has raised $14M in a Series A financing on Jan 30, 2020. The investment was led by ARCH Venture Partners and Northpond Ventures.